When the use of medications is indicated, tamoxifen is the preferred option for reducing the risk of primary breast cancer in premenopausal women, while raloxifene and aromatase inhibitors are preferred for postmenopausal women. This evidence concerns the gene CYP19A1 and breast carcinoma.